- Title
- Pneumococcal polysaccharide vaccine is a cost saving strategy for prevention of acute coronary syndrome
- Creator
- Ren, Shu; Attia, John; Li, Shu Chuen; Newby, David
- Relation
- Vaccine Vol. 39, Issue 12, p. 1721-1726
- Publisher Link
- http://dx.doi.org/10.1016/j.vaccine.2021.02.019
- Publisher
- Elsevier
- Resource Type
- journal article
- Date
- 2021
- Description
- Objective: There is evidence that the pneumococcal polysaccharide vaccine (PPV) may reduce cardiovascular disease. We aimed to evaluate the cost-effectiveness of PPV for primary prevention of acute coronary syndrome (ACS) in the elderly in Australia. Methods: A Markov model was developed to investigate the costs, QALYs and ICERs of PPV administration in those aged ≥65 years without a history of ACS from the perspective of Australian healthcare system, using elderly-specific clinical data and local costs from Australian Heart Foundation and Australian Institute of Health and Welfare databases. A ten-years horizon was used, and all costs and health outcomes were discounted at 5% annually. The impact of various assumptions was tested with sensitivity analyses. Results: In the base-case analysis, interventional strategy (100% PPV coverage) prevented an additional five incident ACS events among 1000 “healthy” elderly individuals compared with standard of care (50% PPV coverage) over 10 years. 100% PPV was the dominant strategy, resulting in a QALY gain of 0.0075 and cost saving of AU$ 179 per person. The results were most sensitive to effectiveness of PPV at preventing ACS and reducing hospital bed-days, and cost of ACS admission, but in all sensitivity analyses 100% PPV remained the dominant strategy. Shortening the time horizon from ten to five years resulted in further cost saving. Conclusion: PPV for the prevention of ACS in those aged ≥65 is a dominant intervention strategy, with cost saving and minor improvements in QALY. Healthcare providers should promote PPV administration for all eligible populations.
- Subject
- pneumococcal polysaccharide vaccine; atheroscelerosis; acute coronary syndrome; cardiovascular disease; health economic analysis; cost-utility analysis; public health; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1444943
- Identifier
- uon:42453
- Identifier
- ISSN:0264-410X
- Language
- eng
- Reviewed
- Hits: 683
- Visitors: 674
- Downloads: 0
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format |
|---|